Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of BPX-501 T Cells After Haploidentical HSCT
NCT02487459Phase 1Withdrawn
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Jul 2016
- Primary completion
- Jun 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivogenlecleucel in hematologic malignancy, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and 4 more, sponsored by Bellicum Pharmaceuticals, Inc. Primary endpoint: Adverse events at 2 years. Planned start Jul 2016; status: withdrawn.
02
Drugs
rivogenlecleucel
03
Conditions
hematologic malignancyacute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02487459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487459.